Shares of Kamada Ltd (NASDAQ:KMDA) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price objective of $8.50 for the company and are predicting that the company will post $0.06 earnings per share for the current quarter, according to Zacks. Zacks has also given Kamada an industry rank of 179 out of 265 based on the ratings given to related companies.

KMDA has been the subject of several analyst reports. Jefferies Group reissued a “buy” rating and issued a $7.00 target price on shares of Kamada in a research note on Thursday, October 12th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Wednesday, October 25th. Finally, ValuEngine raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Friday, January 5th.

Several hedge funds and other institutional investors have recently bought and sold shares of KMDA. Nexthera Capital LP acquired a new position in shares of Kamada during the 2nd quarter valued at about $1,805,000. Paulson & CO. Inc. increased its stake in shares of Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after acquiring an additional 60,000 shares during the last quarter. Worth Venture Partners LLC acquired a new position in shares of Kamada during the 3rd quarter valued at about $246,000. Navellier & Associates Inc acquired a new position in shares of Kamada during the 2nd quarter valued at about $303,000. Finally, Analyst IMS Investment Management Services Ltd. increased its stake in shares of Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares during the last quarter. 6.31% of the stock is owned by institutional investors.

Shares of Kamada (NASDAQ:KMDA) traded down $0.10 during mid-day trading on Wednesday, reaching $5.60. 63,759 shares of the company traded hands, compared to its average volume of 27,384. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73.

Kamada (NASDAQ:KMDA) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.01) earnings per share for the quarter. Kamada had a negative net margin of 1.27% and a negative return on equity of 1.64%. analysts expect that Kamada will post 0.08 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/kamada-ltd-kmda-given-average-rating-of-strong-buy-by-brokerages/1815952.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.